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ackground: Interleukin-37 (IL-37) is a member of IL-1 cytokine family. IL-37 immunosuppresses 
the pathogenesis of rheumatoid arthritis via down-regulating pro-inflammatory cytokines. The 
aim of the current study was to evaluate the expression level of IL-37 in rheumatoid arthritis (RA) 
patients and its correlation with the disease activity score in 28 joints (DAS-28). 
Methods: In the current study, forty-six RA patients, having a ratio of 19 males and 27 females, and twenty 
healthy controls (11 males and 9 females) were included. DAS-28 was measured on the basis of patients’ 
clinical observations of the tender and swollen joints, physical examination and erythrocyte sedimentation 
rate (ESR). ESR was measured according to the Westergren method. Serum IL-37 level was measured by 
ELISA. Depending upon the DAS28 calculations the patients were divided in four groups as; 19 in 
remission, 6 had mild disease activity, 6 were in moderate state and 15 patients were found with severe 
disease activity.  
Results: Serum IL-37 levels were found markedly raised in RA patients (mean = 862.6) than in healthy 
individuals (mean ± SD = 4.4 ± 1.74 pg/ml). Further, our results suggest that level of IL-37 increased 
significantly from mild (mean ± SD = 829.17 ± 61.40 pg/ml) to moderate (mean ± SD = 1307.5 ± 165.1 
pg/ml) and severe (mean ± SD = 1607 ± 86.8 pg/ml) disease prognosis.  
Conclusion: Thus we conclude, IL-37 has a positive correlation with DAS28 and thus has a potential role 
in RA pathogenesis. 
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Introduction  
Rheumatoid arthritis (RA) is a systemic, chronic 
inflammatory autoimmune disorder characterized by 
immune cells infiltration, inflammatory joints and 
synovial hyperplasia [1]. It primarily affects the 
peripheral joints. The accurate pathogenesis and 
etiology of RA remain elusive, though cytokines are 
considered to play a central role in disease progression 
through inflammation and articular destruction [2]. An 
imbalance between all pro inflammatory and anti-
inflammatory cytokines leads to the progression of 
disease symptoms [3]. RA causes swelling of joints, 
tenderness of joints and also the destruction of synovial 
joints that leads to severe disability and premature 
fatality [4]. Rheumatologists don’t understand the 
obvious cause of RA development but the most possible 
risk factors include genetic background, hormones, 
environmental factors, smoking [5], microbes in the 
bowel and obesity. Middle aged mostly women are 
frequently affected as compared to men [6]. Estimated 
RA prevalence is recorded as 1% worldwide [1]. The 
pathogenesis of RA is a multi-step process and is divided 
as autoimmunity, systemic inflammation and then 
leading to bone destruction. Certain cells of the immune 
system start attacking the healthy tissues causing 
inflammation specifically in the synovium, the tissue 
lining the joints. Due to the detection of auto-antibodies 
including rheumatoid factor (RF) and anti-citrullinated 
protein antibodies (ACPAs), RA is considered to be an 
autoimmune disease [7]. RF is not considered as RA 
specific as it may be detected in hepatitis C viral 
infection and older people whereas ACPA is RA specific 
and plays significant role in RA pathogenesis [8]. RF and 
ACPAs, cause an immune deregulation in RA patients. 
Due to the localization of inflammatory cells in the 
synovial lining of the joints, thickening and hyperplasia 
develop [9].  
Interleukin 37 (IL-37) has been included in 
interleukin 1 cytokine family (IL1F7) [10,11]. IL-37 is an 
anti-inflammatory cytokine and has a potential role in 
various inflammatory diseases like ankylosing 
spondylitis [12], graves’ disease [13], rheumatoid 
arthritis [14], systemic lupus erythematosus (SLE) [15] 
and inflammatory bowel disease [16].  High levels of IL-
37 are detected in the serum and synovial fluid of all RA 
patients with different ranges depending upon the 
severity of the disease. Elevated IL-37 level inhibits pro 
inflammatory cytokines synthesis [17]. IL-37 has anti-
inflammatory activity in both innate and acquired 
immunity. It plays a significant role in the control of RA 
pathogenesis by suppressing inflammation and innate 
immunity. Injecting IL-37 is considered to be the novel 
RA therapy. It functions as a down regulator of local and 
systemic inflammations [18]. It is expressed in various 
cells, tissues and organs including plasma cells, 
monocytes, epithelial cells, macrophages, dendritic cells, 
thymus, testis and uterus [19]. Its specific role is to down 
regulate inflammation, innate immunity and adaptive 
immunity. Lipo-polysaccharides (LPS) may also be 
induced for the maintenance of IL-37 expression levels 
in RA patients so that it might not be completely 
diminished. Treatment with LPS is found very helpful in 
the improvement of lungs and kidneys functioning and 
also in the prevention of liver damage [20].  
Disease Activity Score (DAS) is a scoring strategy 
implies for the evaluation of disease severity of RA [21]. 
DAS28 includes 28 joints to be examined. DAS28 is 
calculated on the basis of number of all swollen and 
tender joints [21], visual assessment of patients’ disease 
severity and erythrocyte sedimentation rate (ESR). ESR 
is required for indicating the degree of inflammation. 
RA treatment therapies can slow down the joint 
deterioration and inflammation leading to disability. On 
the basis of DAS28, RA patients can be categorized in 
four levels; in remission DAS28<2.6, in low disease 
activity DAS28≤3.2, in moderate disease activity 
DAS≤5.1 and in high or severe disease activity 
DAS28>5.1 [21]. DAS28 evaluation every four weeks 
can help your doctors and you to decide whether your 
treatment needs any changes for further improvements 
[22]. Disease activity scoring was made to evaluate the 
disease severity of the patients clinically to minimize 
other related complications and also to modify the 
treatment therapy according to the severity level of the 
disease. Originally DAS was developed to assess the 
disease onset in early affected RA patients. Newly 
developed indices for DAS evaluation are to investigate 
the severity of patients in early stage as well as in the 
severe diseased. DAS28 is now considered and more 
preferable and simple method for the evaluation of RA 
subjects. 
The current study demonstrates, the serum level of IL-
37 in RA patients and its correlation with DAS28 score 
in inactive and severely diseased patients. 
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Methods 
Patients and clinical evaluations: 
Forty-six RA patients from Sharif Medical City hospital 
Lahore-Pakistan were included in this study. Patients 
fulfilling the Rheumatology criteria of American College 
of Rheumatology were selected. In addition, twenty 
healthy individuals of more than 30 years of age were 
taken as controls. This study was first approved by the 
institutional Ethical Review Board (ERB) of Imperial 
College of Business Sciences (ICBS), Lahore-Pakistan. 
Informed consent was signed from all the study 
participants and counseling, related to our further 
investigations, was done before subjecting the patients.  
All patients were presented with varying symptoms 
and complaints. The total count of tender and swollen 
joints of each patient was calculated on DAS28 score; 
ESR was tested on immediate basis and disease severity 
was assessed for DAS28 calculations. DAS28 grouping 
was done according to the disease severity of the 
patients. On the basis of DAS28 evaluations, all patients 
(n=46) were divided in four groups: remission 
(DAS28≤2.6), mild (2.6<DAS28≤3.2), moderate 
(3.2<DAS28≤5.1) and severe (DAS28>5.1). While 
examining the patient clinically, blood samples were 
collected for ESR and interleukin level measurement.  
Serum IL-37 level measurement: 
Clotted blood samples were centrifuged at 1300 g (RCF) 
for 10 minutes and serum was separated in specifically 
labeled serum cups. All the samples were stored at 
freezing temperature until analysis. Serum IL-37 level of 
all the samples was detected via enzyme linked 
immunosorbent assay (ELISA) (Cusabio CSB E16185h). 
IL-37 specific antibody was pre-coated on microplate. 
100 μl standard and samples were loaded in allocated 
wells and incubated for 2 hours at 37oC. Wells were 
washed twice to remove unbound proteins. 100 μl of 
biotin antibody was added and plate was wrapped in 
aluminum foil and incubated at 37oC for 1 hour. After 
incubation and washing, 100 μl horse radish peroxidase 
(HRP) avidin solution was added and incubated for one 
hour. Wells were again washed; 90 μl TMB substrate was 
added and kept in dark for 30 minutes. Color reaction 
developed was directly proportional to the presence of 
IL-37 levels in it. After incubation, 50 μl of stop solution 
was added. OD values of the microplate were recorded 
at 450nm. 
Statistical analysis: 
Prism Graph Pad was used to analyze the data. Unpaired 
t-test was employed to determine statistically significant 
difference among various diseased groups. The 
difference was significant when p value was less than 
0.05. The correlation between IL-37 level and DAS28 
was analyzed by Pearson’s test. Significant correlation 
was evaluated as P<0.05. 
Results 
Clinical assessment of research subjects: 
For the evaluation of serum IL-37 expression levels, 
forty-six RA patients (19 males and 27 females) average 
age of 51 years (ranged from 33 to 79 years) and twenty 
healthy controls (11 males and 09 females) average age 
of 43 years (ranged from 36 to 53 years) were included. 
DAS28 results were analyzed on the basis of tender and 
swollen joints count, ESR and the physical severity of the 
disease regarding patients’ pain (table 1). On the basis of 
DAS28 results, 46 RA patients were divided; 19 
remission, 6 mild, 6 moderate and 15 in severe disease 
activity group. 
Characteristics RA patients 
(n=46) 
Healthy 
controls (n=20) 
Age 51 (33-79) 43 (36-53) 
Gender (male: female) 19: 27 11:09 
Swollen joints 4 (0-18) ___ 
Tender joints 3 (0-18) ___ 
ESR results (mm/hour) 35 (10-99) 10 (4-17) 
DAS28 grouping 
Remission 
(DAS28 ≤2.6) 
19 patients __ 
Mild 
(2.6<DAS28≤3.2) 
06 patients __ 
Moderate 
(3.2<DAS28≤5.1) 
06 patients __ 
Severe 
(DAS28>5.1) 
15 patients __ 
Table 1: Clinical features of all research subjects 
Gender ratio: 
Among healthy individuals, 11 were males and 9 were 
females. Accordingly the gender ratio of RA patients 
included, 19 patients were male and 27 were of female 
gender. RA remission patients were 10 males and 9 
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females. Out of six patients from mild group, 2 were 
males and 4 were females. Moderate group patients 
included 2 males and 4 females. In severe diseased 
patients, 5 were males and 10 were females. (Figure 1) 
 
Figure 1: Graphical representation of gender distribution of healthy 
individuals and all RA groups 
Serum IL-37 measurement: 
The level of IL-37 in healthy controls’ serum was 
remarkably low, mean ± SD = 4.4 ± 1.7 pg/ml. On 
contrary, it was markedly raised in RA patients with 
mean = 862.6 pg/ml. Interestingly, IL-37 level increased 
significantly with disease projection from mild to 
moderate and severe conditions. Concisely, in 
remission patients the IL-37 level (mean ± SD = 145.16 
± 48.39 pg/ml) was lowest among the four categories. 
Additionally, the level of IL-37 in the mild, moderate 
and severe patients was observed to be [mean ± SD] 
829.17 ± 61.40 pg/ml, 1307.5 ± 165.1 pg/ml and 1607 ± 
86.8 pg/ml respectively (Table 2) (Figure 2). 
IL-37 ELISA results (pg/ml) 
 Control 
Group 
Remission 
Group 
Mild 
Group 
Moderate 
Group 
Severe 
Diseased 
Group 
Mean 4.46 145.16 829.17 1307.5 1607 
Standard 
Deviation 
1.74 48.39 61.40 165.1 86.8 
Table 2: IL-37 ELISA results of Healthy Controls and RA patients 
Serum IL-37 level and DAS28 correlation: 
Serum IL-37 level was found markedly low in all healthy 
controls having no chronic or inflammatory diseases, 
while it was found strongly elevated in all RA patients. 
Interleukin levels and disease severity was correlated. 
The P value of correlation between serum IL-37 patients 
and DAS28 of RA subjects was significant (P<0.05) 
(Table 3). Our results demonstrated that the correlation 
between remission (-0.018), mild (-0.077) and 
moderate (-0.307) patient groups and IL37 was 
negative. However, the IL37 level was positively 
correlated with severe patients (0.168). 
 
Figure 2: Graphical representation of the serum level of IL-37 
detected among different disease group patients i.e., Remission 
(n=19), Mild (n=6), Moderate (n=6) and Severe (n=15). The data is 
statistically analyzed by unpaired t-test. Data is statistically significant 
when p < 0.05. 
Discussion  
RA is a systemic, chronic inflammatory and 
autoimmune disease having cell infiltration, 
uncontrolled synovial cells proliferation and cartilage 
destruction [23]. Numerous studies have reported the 
elevated levels of pro inflammatory cytokines such as 
TNF, IL-1 and IL-6 in RA patients. Inhibition of these 
inflammatory cytokines is considered to be the 
treatment goal for such patients [24]. Most of the pro 
inflammatory cytokines have a potential role in the 
pathogenesis of the disease, as their serum and synovial 
fluid levels are significantly raised [4,25]. In various 
inflammatory autoimmune diseases IL-37, an anti-
inflammatory cytokine, levels increases with the 
increase of inflammatory cytokines [17]. Thus IL-37 has 
been emerged as a novel anti-inflammatory cytokines 
that possesses extra- and intracellular properties. It 
suppresses inflammation and the innate immune 
responses [26]. Its potential protective role is noticed in 
several animal models such LPS induced shock [27], 
dextran sulphate sodium induced colitis [28], insulin 
resistance and obesity induced inflammation, hepatitis 
B virus infection [29], Aspergillus infection [30], Graves’ 
disease and concanavalin A-induced hepatitis. On the 
other hand, down-regulation of IL-37 expression is 
observed in Bechet’s disease [31], invertebral disc 
regeneration [32] and Vogt-Koyanagi-Harada disease 
[33].  
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In the current study we are reporting the correlation of 
IL-37 level with the prognosis of RA in Pakistani 
population, which was not reported before. Our data 
demonstrated the increased serum IL-37 level all RA 
patients (mean = 862.6 pg/ml) and was reduced 
considerably in healthy individuals (mean ± SD was 4.4 
± 1.7 pg/ml). Published studies suggest the significant 
relation between the IL-37 level and the disease activity 
and pro-inflammatory cytokines production. Yang L et 
al, reported a positive correlation of elevated IL-37 with 
pro-inflammatory cytokines and disease activity in all 
RA patients [8, 13]. It has been reported that immune 
histochemical staining of synovial lining of RA patients 
have elevated IL-37 level as compared to healthy 
controls [20]. The current study demonstrated that 
serum IL-37 level was markedly low in remission RA 
(mean ± SD = 145.16 ± 48.39 pg/ml) patients than 
severely diseased active RA patients (1607 ± 86.8 pg/ml) 
suggesting that remission RA patients had low pro- 
inflammatory cytokines and decreased symptoms and 
joint complications. This suggests that elevated 
production of pro-inflammatory cytokines might have 
triggered the elevated levels of  IL-37 [3]. Both pro- and 
anti-inflammatory cytokines levels are known to be 
raised in RA patients. Sequentially, the presence of pro-
inflammatory cytokines may up regulate the production 
of IL-37 [17] and IL-37 may down regulate the excessive 
level of pro- inflammatory cytokines [19]. Although the 
expression level of IL-37 is high in severe active RA 
patients, however as compared to the level of pro- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
inflammatory cytokines it is still low, and one of the 
most probable reasons of disease progression in such 
patients [34]. Thus the uncontrolled inflammation in 
RA patients is due to inadequate working of antagonistic 
cytokines, specifically IL-37 [19]. A previous study has 
shown that in all the inactive remission state patients 
there was significantly decreased level of serum IL-37 
and was majorly regulated by pro-inflammatory 
cytokines [3]. Based on our results and previously 
reported results, it is hypothesized that IL-37 produced 
due to activated immune responses has a vital role in RA 
pathogenesis, and promote inflammation via 
suppression of pro-inflammatory cytokines.  
In current study, we demonstrated that serum IL-37 
level had positive correlation with DAS28 in RA patients 
(p < 0.05). Consistent with the results, a positive 
correlation of IL-37 and DAS28 was previously recorded 
in China among 50 RA patients [3] and in Changhai 
among 34 RA patients [19].  Thus, IL-37 is the most 
probable biomarker of RA diagnostics, disease activity 
evaluation and remedial response observations [35]. The 
results of the present study demonstrated that women 
were more frequently affected by RA as compared to 
men (27 females and 19 males). It was reported in Oslo 
that the prevalence of RA in females was two times 
greater than in men [36]. Jacquiline has also reported 
that females are affected two to three times greater as 
compared to males. Moreover it has been noticed that in 
majority of the autoimmune diseases females are 
predominantly affected [37].  
 Remission Group 
DAS28  
Mild Group 
DAS28 
Moderate 
DAS28 
Severe Group 
DAS28 
Remission Group ELISA 
IL-37 Results (pg/ml) 
Pearson Correlation 0.0001* … … … 
Sig. (2-tailed) -0.018 … … … 
N 19 … … … 
Mild Group ELISA IL-
37 Results (pg/ml) 
Pearson Correlation … .0009** … … 
Sig. (2-tailed) … -0.077 … … 
N … 6 … … 
Moderate ELISA IL-37 
Results (pg/ml) 
Pearson Correlation … … .00001** … 
Sig. (2-tailed) … … -0.307 … 
N … … 6 … 
Severe Group IL-37 
Results (pg/ml) 
Pearson Correlation … … … .0001* 
Sig. (2-tailed) … … …. 0.168 
N … … … 15 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
Table 3: Correlation of IL-37 levels in RA DAS28 grouping  
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In conclusion, the level of IL-37 in serum was 
markedly high in RA patients, in Pakistani population, 
specifically in the severe diseased patients. Positive 
correlation was demonstrated between IL-37 levels and 
disease severity (with P value less than 0.05). The 
limitation of the current study is that, we could not 
investigate the serum level of other anti and pro-
inflammatory cytokines and their correlation with the 
level of IL-37.  However, the current data highlights the 
fact that increased serum IL-37 has a potential anti-
inflammatory role in RA pathogenesis. 
Conflict of Interests 
Authors declare that there is no conflict of interest for 
publishing this study. 
Acknowledgement 
The Study was supported by Faculty of Health and 
Allied Sciences, Imperial College of Business Studies. 
References 
1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature, 
(2003); 423(6937): 356–61.  
2. Brennan FM, McInnes IB. Evidence that cytokines play a role in 
rheumatoid arthritis. Journal of Clinical Investigation. 
2008;118(11):3537–45.  
3. Zhao PW, Jiang WG, Wang L, Jiang ZY, Shan YX, et al. Plasma 
levels of IL-37 and correlation with TNF-a, IL-17A, and Disease 
activity during DMARD treatment of rheumatoid arthritis. PLoS 
One. 2014;9(5).  
4. Wolfe F. The natural history of rheumatoid arthritis. Journal of 
Rheumatology. (1996) ; 44:13–22.  
5. Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet, 
(2017); 12: 376(9746):1094–108.  
6. Crowson CS, Matteson EL, Myasoedova E, Michet CJ, Ernste FC, 
Warrington KJ, et al. The lifetime risk of adult-onset rheumatoid 
arthritis and other inflammatory autoimmune rheumatic 
diseases. Arthritis & Rheumatism, (2011); 63(3): 633–9.  
7. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New 
therapies for treatment of rheumatoid arthritis. Lancet, (2016); 
370(9602): 1861–74.  
8. Balsa A, Cabezón A, Orozco G, Cobo T, Miranda-Carus E, et al. 
Influence of HLA DRB1 alleles in the susceptibility of 
rheumatoid arthritis and the regulation of antibodies against 
citrullinated proteins and rheumatoid factor. Arthritis Research 
& Therapy, (2010); 12(2): R62.  
9. Tarner IH, Harle P, Muller-Ladner U, Gay RE, Gay S. The 
different stages of synovitis: acute vs chronic, early vs late and 
non-erosive vs erosive. Best Practice & Research: Clinical 
Rheumatology, (2005); 19(1): 19–35.  
10. Busfield SJ, Comrack CA, Yu G, Chickering TW, Smutko JS, et 
al. Identification and gene organization of three novel members 
of the IL-1 family on human chromosome 2. Genomics, (2000); 
66(2): 213–6.  
11. Smith DE, Renshaw BR, Ketchem RR, Kubin M, Garka KE, et al. 
Four new members expand the interleukin-1 superfamily. The 
Journal of Biological Chemistry, (2000); 275(2): 1169–75.  
12. Chen B, Huang K, Ye L, Li Y, Zhang J, Zhang J, et al. Interleukin-
37 is increased in ankylosing spondylitis patients and associated 
with disease activity. Journal of Translational Medicine, (2015); 
13: 36.  
13. Xia S, Wei J, Wang J, Sun H, Zheng W, Li Y, et al. A requirement 
of dendritic cell-derived interleukin-27 for the tumor infiltration 
of regulatory T cells. Journal of Leukocyte Biology, (2014); 95(5): 
733–42.  
14. Yang L, Zhang J, Tao J, Lu T. Elevated serum levels of 
Interleukin-37 are associated with inflammatory cytokines and 
disease activity in rheumatoid arthritis. Acta Pathologica, 
Microbiologica et Immunologica Scandinavica, (2015); 123(12): 
1025–31.  
15. Ye L, Ji L, Wen Z, Zhou Y, Hu D, Li Y, et al. IL-37 inhibits the 
production of inflammatory cytokines in peripheral blood 
mononuclear cells of patients with systemic lupus 
erythematosus: its correlation with disease activity. Journal of 
Translational Medicine, (2014); 12: 69.  
16. Weidlich S, Bulau A-M, Schwerd T, Althans J, Kappler R, 
Koletzko S, et al. Intestinal expression of the anti-inflammatory 
interleukin-1 homologue IL-37 in pediatric inflammatory bowel 
disease. Journal of Pediatric Gastroenterology and Nutrition, 
(2014); 59(2): e18-26.  
17. Boraschi D, Lucchesi D, Hainzl S, Leitner M, Maier E, et al. IL-
37: A new anti-inflammatory cytokine of the IL-1 family. 
European Cytokine Network, (2011); 22(3): 127–47.  
18. Xu S, Li W, Tong Y, Dong N, Sheng Z, Yao Y. Expression of IL-
37 contributes to the immunosuppressive property of human 
CD4 + CD25 + regulatory T cells. Scientific Reports, (2015); 5: 
14478. 
19. Xia T, Zheng XF, Qian BH, Fang H, Wang JJ, et al. Plasma 
interleukin-37 is elevated in patients with rheumatoid arthritis: 
Its correlation with disease activity and Th1/Th2/Th17-related 
cytokines. Disease Markers, (2015); 2015: 795043.  
20. Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, et al. 
IL-37 is a fundamental inhibitor of innate immunity. Nature 
Immunology, (2010); 11(11): 1014–22. 
21. Matsui T, Kuga Y, Kaneko A, Nishino J, Eto Y, et al. Disease 
Activity Score 28 (DAS28) using C-reactive protein 
underestimates disease activity and overestimates EULAR 
response criteria compared with DAS28 using erythrocyte 
sedimentation rate in a large observational cohort of rheumatoid 
arthritis patients. Annals of the Rheumatic Diseases, (2007); 
66(9): 1221–6.  
22. Fransen J, Stucki G, van Riel PLCM. Rheumatoid arthritis 
measures: Disease Activity Score (DAS), Disease Activity Score-
28 (DAS28), Rapid Assessment of Disease Activity in 
Rheumatology (RADAR), and Rheumatoid Arthritis Disease 
Activity Index (RADAI). Arthritis & Rheumatology, (2003); 
49(S5): S214–24.  
23. Biswas S, Sharma S, Saroha A, Bhakuni DS, Malhotra R, et al. 
Identification of novel autoantigen in the synovial fluid of 
rheumatoid arthritis patients using an immunoproteomics 
approach. PLoS One. 2013;8(2): e56246.  
24. Hurkmans E, van der Giesen FJ, Vliet Vlieland TP, Schoones J, 
Van den Ende ECHM. Dynamic exercise programs (aerobic 
capacity and/or muscle strength training) in patients with 
                                                               
 
 
 
                     Advancements in Life Sciences  |  www.als-journal.com  |  August 2018  | Volume 5  |  Issue 4    165 
 
als 
You’re reading Expression level of serum Interleukin-37 in Rheumatoid Arthritis patients and its correlation with Disease Activity 
Score 
 
rheumatoid arthritis. The Cochrane Database of Systematic 
Reviews, (2009); (4): CD006853.  
25. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, et al. 
Association of chronic inflammation, not its treatment, with 
increased lymphoma risk in rheumatoid arthritis. Arthritis & 
Rheumatology, (2006); 54(3): 692–701.  
26. Bulau AM, Nold MF, Li S, Nold-Petry CA, Fink M, et al. Role of 
caspase-1 in nuclear translocation of IL-37, release of the 
cytokine, and IL-37 inhibition of innate immune responses. 
Proceedings of the National Academy of Sciences of the United 
States of America, (2014); 111(7): 2650–5.  
27. Feldmann M, Maini RN. The role of cytokines in the 
pathogenesis of rheumatoid arthritis. Rheumatology (Oxford), 
(1999); 38(2): 3-7.  
28. Mcnamee EN, Masterson JC, Jedlicka P, Mcmanus M, Grenz A, 
et al. Interleukin 37 expression protects mice from colitis. 
Proceedings of the National Academy of Sciences of the United 
States of America, (2011); 108(40): 16711–6.  
29. Li C, Ji H, Cai Y, Ayana DA, Lv P, et al. Serum interleukin-37 
concentrations and HBeAg seroconversion in chronic HBV 
patients during telbivudine treatment. Journal of Interferon & 
Cytokine Research, (2013); 33(10):612–8.  
30. Moretti S, Bozza S, Oikonomou V, Renga G, Casagrande A, 
Iannitti RG, et al. IL-37 inhibits inflammasome activation and 
disease severity in murine aspergillosis. PLOS Pathogens, (2014); 
10(11): e1004462.  
31. Ye Z, Wang C, Kijlstra A, Zhou X, Yang P. A possible role for 
interleukin 37 in the pathogenesis of Behcet’s disease. Current 
Molecular Medicine, (2014); 14(4): 535–42.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
32. Wan ZY, Sun Z, Song F, Chen YF, Zhang WL, Wang HQ, et al. 
Downregulated interleukin 37 expression associated with 
aggravation of intervertebral disc degeneration. International 
Journal of Clinical and Experimental Pathology, (2014); 7(2): 
656–62.  
33. Ye Z, Wang C, Tang J, Zhou Y, Bai L, Liu Y, et al. Decreased 
interleukin-37 expression in Vogt-Koyanagi-Harada disease and 
upregulation following immunosuppressive treatment. Journal 
of Interferon & Cytokine Research, (2015); 35(4): 265–72.  
34. Isomaki P, Punnonen J. Pro- and anti-inflammatory cytokines in 
rheumatoid arthritis. Annals of Medicine, (1997); 29(6): 499–
507.  
35. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, et 
al. The American College of Rheumatology preliminary core set 
of disease activity measures for rheumatoid arthritis clinical 
trials. The Committee on Outcome Measures in Rheumatoid 
Arthritis Clinical Trials. TL  - 36. Arthritis & Rheumatology, 
1993; 36(6): 729–40.  
36. Kvien TK, Uhlig T, Odegard S, Heiberg MS. Epidemiological 
aspects of rheumatoid arthritis: the sex ratio. Annals of the New 
York Academy of Sciences, (2006); 1069: 212–22.  
37. Oliver JE, Silman AJ. Why are women predisposed to 
autoimmune rheumatic diseases? Arthritis Research & Therapy, 
(2009); 9: 1–9. 
 
This work is licensed under a Creative 
Commons Attribution-Non Commercial 4.0 
International License. To read the copy of this license please visit:  
https://creativecommons.org/licenses/by-nc/4.0/ 
 
